Journal of Clinical Oncology
Articles in this Issue
Prognostic value of systemic inflammation in early-stage breast cancer in the CANTO cohort (SIM-CANTO).
566 Background: The importance of host anti-tumor immunity in early-stage breast cancer (eBC) is now well recognised. Neutrophil / lymphocyte ratio (NLR)...
Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).
8014 Background: At the first planned interim analysis of ADRIATIC, consolidation D significantly improved the dual primary endpoints of overall and progr...
Frailty in motion: How Fitbit data reflects patients with cancers' functional status in the All-of-Us database.
1561 Background: Frailty is a vital determinant of outcomes in adults with cancer, leading to heightened toxicity, morbidity, and reduced survival. Despit...
Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study.
e13016 Background: Pyrotinib is an irreversible tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4. Multiple studies have demonstrated the effic...
A phase Ia study to estimate the radiochemical and radiation safety of of <sup>68</sup> Ga-NYM032, a PSMA-targeted radioligand.
e17039 Background: 68 Ga-NYM032 is a radiolabeled small-molecule targeting prostate-specific membrane antigen (PSMA), designed as an imaging a...
Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC).
1076 Background: T-DXd and SG are antibody-drug conjugates (ADCs) increasingly used in HER2-negative BC, however, there are insufficient data to guide ADC...
Transforming genomic testing in prostate cancer: A comprehensive system-wide initiative.
11139 Background: Timely detection of pathogenic variants enables personalized treatment and improved outcomes in prostate cancer (PC). In 2020, NCCN guid...
Disparities in supportive care breast cancer clinical trial enrollment.
e13786 Background: Supportive care clinical trials (CTs) are crucial for improving breast cancer (BC) survivorship, yet the representation of diverse demo...
Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).
5057 Background: mCRPC with high neoantigen burden due to DNA mismatch repair deficiency (MMRd) and somatic hypermutation, or CDK12...
Socioeconomic disparities in access to and outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC).
e16337 Background: HCC is a leading indication for liver transplantation (LT) and a major contributor to cancer-related mortality worldwide. Access to LT...
Cancer patients’ views on clinical research in Brazil: Concerns, knowledge, and misconceptions—A national survey.
e23045 Background: Brazil’s participation in clinical research (CR) remains limited. Unawareness of CR benefits is a key barrier. Understanding patient pe...
Metastatic pancreatic cancer: Molecular characterization, therapeutic implications, and survival outcomes from community oncology practice in western India.
e16400 Background: Pancreatic cancer is a highly aggressive malignancy associated with poor survival outcomes. Next-generation sequencing (NGS) enables th...
A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study.
e17135 Background: While Prostate Specific Antigen (PSA) is the standard of care for prostate cancer screening, it is highly controversial due to the perf...
Time toxicity of intravesical sequential gemcitabine and docetaxel.
e23098 Background: While bacillus Calmette-Guérin (BCG) is the gold standard adjuvant therapy for high-risk non-muscle invasive bladder cancer (NMIBC) fol...
Role of intratumoural bacteria in resistance to LAG-3 targeting therapeutics.
e14648 Background: Intratumoural bacteria play a pivotal role in the tumour microenvironment (TME) and may influence clinical trial outcomes. Here, we foc...
Clinical outcomes of black versus non-Hispanic white women with stage IV breast cancer treated with sacituzumab at Emory.
e13141 Background: Black women (BW) experience higher rates of advanced breast cancer and the aggressive triple negative subtype compared to Non-Hispanic...
The correlation of two SNPs in the DRACHmotif with gefitinib-induced hepatotoxicity in patients with non-small cell lung cancer.
e20644 Background: Drug-induced liver injury (DILI) represents a significant safety concern in drug development and clinical therapy. Severe hepatotoxicit...
Economic outcomes of palliative care in colorectal cancer hospitalizations: A propensity-matched retrospective cohort study on resource utilization.
12098 Background: The economic burden of colorectal cancer (CRC), a major cause of cancer-related death worldwide, is significant and is fueled by extende...
Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients.
e15038 Background: The role of circulating tumor cells (CTCs) has been well established in the prediction of survival in metastatic settings, namely breas...
The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory analysis from the phase 3 FRUTIGA study.
e16011 Background: For the second- and third-line (2/3L) treatment of advanced gastric cancer (GC), chemotherapy (C) remains the main modality, while a ty...
NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy.
TPS9609 Background: High-risk clinical stage II melanoma patients are already indicated for adjuvant anti-PD-1 therapy, regardless of the sentinel lymph n...
Disparities in mortality from hematological malignancies with pulmonary embolism: Insights from US national data.
e18604 Background: Hematological malignancies (HM) and pulmonary embolism (PE) create a critical clinical challenge, with PE being the second leading caus...
Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).
3504 Background: Among patients with resected node-positive colon cancer, nearly 30% will relapse despite standard adjuvant chemotherapy. Analysis of mole...
A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with osseous metastases (RADICAL/Alliance A031801).
TPS4616 Background: Osseous metastases (OM) occur in approximately 30% patients with advanced RCC. Despite therapeutic advances, OM are associated with po...
Does early versus late initiation of immunotherapy in extensive-stage small cell lung cancer affect survival outcomes?
8099 Background: Small cell lung cancer (SCLC) is an aggressive malignancy characterized by a rapid doubling time, high metastatic potential, and risk for...